We’re a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD). Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for conditions that are still widely untreated.
We recognize the vitally important work PMDD advocate and patient groups play in raising awareness of PMDD amongst both practitioners and patients. We understand the unique challenges of PMDD, with diagnosis frequently taking many years. We are committed to working responsibly with PMDD advocates to make PMDD mainstream and increase diagnosis. Every PMDD patient has the right to know they have PMDD,and every friend and relative of a PMDD patient has the right to understand the condition.
There is a large unmet need for support amongst PMDD patients and their families. Patient groups play a vital role in providing such support and knowledge. At Asarina Pharma we recognize and value this and intend to support it as and where we can.
Me v PMDD
Me v PMDD is a symptom and treatment tracking app for Premenstrual Dysphoric Disorder (PMDD). With PMDD, symptom tracking is crucial to ensuring an accurate diagnosis, assessing treatments, and managing the disorder long-term. Me v PMDD makes this tracking intuitive and straightforward, empowering the PMDD Warriors who use it to fight back against the debilitating symptoms armed with tracking, resources, and support.
Brett and Sheila Buchert, a daughter-mother team, launched Me v PMDD, Inc. in St. Petersburg, Florida, USA in May 2017, and currently serve as CEO and COO, respectively. The inspiration to create Me v PMDD arose out of Brett’s own battle with severe (yet intermittent) mental health symptoms and her 10-year journey for the right diagnosis: PMDD. Symptom tracking saved Brett’s life, so she and her #1 PMDD Supporter/Mother, Sheila, are positive that symptom tracking with Me v PMDD can help others living with Premenstrual Dysphoric Disorder find answers, treatment, community, and hope.
The Me v PMDD app launched in December 2017 (free on iOS and Android) and now has over 45,000 downloads, growing daily.
Disclaimer: While our #PMDDandMe2020 Conference sponsors have officially partnered with us for this event. No sponsor or partner has had influence over the event itself or other speakers, delegates, attendees, exhibition including stands or content presented, displayed or live streamed (other than their own provided for the allocated presentation or exhibition stand as appropriate).